Bausch + Lomb Licenses New Technology with Potential to Treat Millions Affected by Ocular Redness

Read the Entire article

Bausch + Lomb, the global eye health company, has acquired an exclusive global license to a new platform technology that may lead to a faster, more effective and longer lasting treatment for ocular redness, a bothersome condition that impacts millions of people worldwide.

The technology employs a different mechanism of action to relieve ocular redness than currently available redness relief products, using a uniquely formulated low dose of brimonidine. Licensed from Eye Therapies, LLC, a privately held biopharmaceutical company, the technology was developed in collaboration with Ora Inc., a private research organization.

One of the most common ophthalmologic conditions, ocular redness, or hyperemia, can be triggered by contact lens wear, dry eye, ocular allergies, lifestyle and environmental factors and medication side effects, among other causes.

Ocular redness is associated with reduced quality of life and negative social connotations, and may impact compliance with certain medications,” explained Dr. Cal Roberts, chief medical officer, Bausch + Lomb. “The decision to license this promising new technology underscores our continued commitment to delivering solutions for physicians and their patients.